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Abstract
Background: Immunotactoid glomerulopathy (ITG) is a rare cause of proteinuria characterized by organized
microtubular deposits in the glomerulus. ITG has been associated with underlying lymphoproliferative disorders and
any renal impairment may be reversible with treatment of the concomitant hematologic malignancy. This case is the
first reported in literature where diffuse large B cell lymphoma developed two years following the initial ITG diagnosis.
Case presentation: A 55-year-old woman with a history of well-controlled diabetes mellitus and thalassemia trait
presented with proteinuria (830 mg/day) in 2010. Initially, she was managed with renin-angiotensin-aldosterone-system
blockade. In 2012, the proteinuria worsened (4.3 g/day) and a renal biopsy showed immunotactoid glomerulopathy
(Fig. 1). Despite extensive work up, no lymphoproliferative disorder was initially found. In January 2014, the patient
presented with a soft-palate mass found on biopsy to be diffuse large B-cell lymphoma. She received 6 cycles of
R-CHOP, 4 cycles of high dose methotrexate chemotherapy for CNS prophylaxis and 30 Gy of Intensity Modulated
Radiation Therapy. Follow-up revealed complete remission of diffuse large B-cell lymphoma and resolution of
proteinuria from the ITG.
Conclusion: As we recognize that patients with ITG may develop hematopoietic neoplasms, close long-term monitoring
is important. Moreover, treatment of the lymphoproliferative disorder can allow for complete remission of ITG.
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Background
Immunotactoid Glomerulopathy (ITG) is a rare cause of
proteinuria characterized by Congo-red negative micro-
tubular deposits in the glomerulus, which are often
monoclonal [1, 2]. There has been controversy in recent
years regarding the distinction between fibrillary glomer-
ulonephritis (FGN) and ITG, due to lack of clinical
significance and overlap in the size of deposited fibrils
[3]. However, many recent studies have shown an
important correlation between monoclonal gammopathy
or lymphoproliferative disorders (LPD) and organized
tubular deposits in the glomerulus as seen in ITG [4–7].
In fact, in a study of 16 ITG patients by Nasr and
colleagues (2012) [6], there was a serum-M spike in
63 % and a hematologic malignancy in 38 % of the
patients. As seen in our case, multiple studies have
found remission of the nephrotic syndrome with therapy
directed against the underlying LPD [2, 6]. Thus, it is
important to distinguish ITG from FGN and direct
investigations towards identifying an underlying LPD,
allowing for effective treatment [8].
Monoclonal gammopathy accompanying renal impair-
ment is increasingly being recognized as an independent
entity, and called monoclonal gammopathy of renal sig-
nificance (MGRS) [9]. In patients with MGRS due to
ITG, the current recommendation is to perform thor-
ough investigations to identify an underlying LPD at
the time of diagnosis [8]. In a survey of English
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language literature reporting incidence of LPD in
ITG, the longest duration between initial ITG diag-
nosis and hematopoietic malignancy is 8 months
[10] (Table 1). Most cases have either existing LPD
or are diagnosed concurrently with ITG (Table 1).
We report a case of ITG where the patient devel-
oped a diffuse large B-cell lymphoma (DLBCL) over
twenty months after the initial diagnosis. There is
little guidance regarding the required duration for
LPD surveillance in ITG patients. In fact, there is a
developing opinion that one might institute therapy
for MGRS at the time of the initial diagnosis, but
the initial therapy, in the absence of a specific
neoplastic cellular diagnosis is based on the prob-
ability of a given neoplastic process developing [8].
Case presentation
A 55-year-old woman with a history of well-controlled
diabetes mellitus and alpha-thalassemia trait presented
Fig. 1 Kidney biopsy. a Kidney biopsy histology with H&E staining shows an increased lobular pattern with mesangial expansion in the glomeruli.
b Electron microscopy images at 15000x and 60000x magnification reveals broad tubular structures located in subendothelial and mesangial
areas of the glomeruli, measuring 30 nm in diameter. The kidney biopsy was consistent with ITG
Table 1 Incidence and timing of hematologic malignancy onset in patients diagnosed with Immunotactoid glomerulonephropathy






Onset of hematologic malignancy
Pronovost et al. 1996 [11] 22 - 9/22 Not described
Rosenstock JL et al., 2003 [7] 6 4/6 2/6 Before or concomitant to ITG
diagnosis
Bridoux et al., 2002 [2] 14 5/14 7/14 Before or concomitant to ITG
diagnosis
Nasr SH et al., 2012 [6] 16 10/16 (63 %) 6/16 (38 %) Ranged from 6 years prior to
concomitant diagnosis
Fogo, A. et al., 1993 [12] 6 3/6 1/6 unclear
Jacobson E et al., 2004 [10] 1 1 1 8 months post-ITG diagnosis
Jabur WL et al., 2008 [13] 1 1 1 concurrently
Matsushita et al., 2005 [14] 1 1 1 5 months prior to ITG
Castro JE et al., 2012 [15] 1 1 1 5 years prior to ITG
Vigil et al., 1998 [16] 1 1 1 5 months post-ITG diagnosis
Witzens-Harig M et al., 2007 [17] 1 1 1 3 years prior to ITG
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with proteinuria in 2010. At the time, her medications in-
cluded metformin, sitagliptin, acarbose, and atorvastatin.
On initial exam, her blood pressure was 130/70 mmHg
with a pulse of 78 beats per minute. Apart from a 3/6
systolic ejection murmur, the remainder of the physical
exam was unremarkable There was no abdominal
organomegaly, no lymphadenopathy and no peripheral
edema. Laboratory studies included normal serum elec-
trolytes, a blood urea of 3.7 mmol/L and creatinine of 58
umol/L. Serum biochemistry showed normal electro-
lytes. The HDL was 1.35 mmol/L and the LDL was
2.46 mmol/L. TSH was normal at 0.92 mmol/L and
complement levels were normal. ANA was elevated at
7.3 (normal <1.0). A urinalysis was positive for blood,
but negative for protein. There were 2–4 red cells and
white cells per high power field and the sediment
contained hyaline casts several containing both red and
white blood cells. A 24 h urine collection contained
830 mg of protein.
Despite a normal blood pressure and renal chemistries,
her urinalysis suggested an underlying proliferative form
of glomerulonephritis with the presence of red cells and
hyaline casts containing cells. Hypothesized differential
diagnoses included diabetic nephropathy or a mild
proliferative glomerulonephritis, such as IgA nephropa-
thy. Trandolapril, a renin-angiotensin-aldosterone sys-
tem blocker, was initiated to minimize proteinuria with
the plan to titrate dosage to blood pressure and a
protein excretion rate below 500 mg per day.
The patient was lost to follow-up until February 2012
when she was re-referred for worsening kidney function
and proteinuria. When reviewed again by the nephrolo-
gist, physical examination revealed a blood pressure of
129/80 mmHg lying with a pulse of 78 beats per minute
and 116/79 mmHg sitting with a pulse of 80 beats per
minute. Chest was clear. Heart sounds S1 and S2 were
present with a grade 3/6 systolic ejection murmur,
unchanged from previous examination. There was no
organomegaly, no lower extremity edema, and no skin
lesions.
Renal indices revealed an elevated blood urea at
8.7 mmol/L, creatinine of 84 umol/L, serum albumin
reduced to 28 g/L and mild elevations of her uric acid
(3.78 mmol/L), calcium (2.63 mmol/L) and phosphorus
levels (1.6 mmol/L). Her hemoglobin A1C was 6.2 %. A
random urine sample contained 2.5 g/L of protein and
6.5 mmol/L of creatinine. The sediment contained 2-4
white cells, and red cells and many granular and hyaline
casts, many containing red and white blood cells. The
24 h urine collection showed an increase in proteinuria
to 4.3 g per day. The urine culture grew no organisms.
Hepatitis B surface antigen was negative, Hepatitis B
surface antibody was positive and core antibody was
positive in keeping with a previous infection with
acquired immunity. Hepatitis C antibody was negative.
The parathyroid and thyroid hormone levels remained
normal. Protein electrophoresis showed a discrete band
in the gamma region, with immunofixation confirming
an IgG kappa monoclonal protein. The complement
components were normal and cryoglobulins were absent.
ANA was elevated at 8.6 (abnormal >1.0). The
autoimmune workup was negative for anti-Smith,
Anti-SM-RNP, Anti Scl-70, Anti-Jo, Anti-DNA, CCP
Antibody, and Rheumatoid factor. Her CBC revealed a
worsening microcytic anemia with hemoglobin of 91 g/L
and a lower MCV of 61.5 fL. The ESR was elevated at
66. On endoscopy, she was found to have Barrett’s
oesosphagus and a proton pump inhibitor was started.
Due to worsening proteinuria, a renal biopsy (Fig. 1)
was performed. Of the 28 glomeruli examined, 2 glom-
eruli were globally sclerosed. Most glomeruli had an
increased lobular pattern associated with mild
endocapillary hypercellularity. Small aggregates of poly-
morphonuclear leukocytes were present in some glom-
eruli. No crescents were seen. The mesangial matrix and
the capillary wall thickness were increased (Fig. 1a).
Congo red stain was negative for amyloid. There was
mild focal interstitial fibrosis. Arteries showed focal
intimal and medial thickening. Tubules were atrophic in
small focal areas. Immunofluorescence showed trace
mesangial smudgy staining for IgM, C3 and fibrinogen.
Electron microscopy (Fig. 1b) showed mostly parallel
tubular structures located in subendothelial and mesan-
gial areas of the glomeruli. The glomerular basement
membrane was mildly thickened in focal areas. The
overall pathologic diagnosis was ITG.
Given the diagnosis of ITG, a hematologic workup was
conducted to investigate a possible underlying LPD.
Repeat serum electrophoresis revealed two discrete
bands in the gamma region with two M proteins quanti-
fied at 2.8 g/L and 0.7 g/L. Quantitative immunoglobu-
lins were 12.5 g/L, 1.84 g/L and 2.77 g/L for IgG, IgA
and IgM respectively. Free kappa was at 64.8 mg/L and
free lambda was 32.9 mg/L with an abnormal ratio 1.97.
Urine immunofixation showed free kappa light chains.
Computed tomography imaging in August 2012 revealed
two elongated nodes in the external iliac areas
measuring 0.6 cm by 2.6 cm without any other lymph-
adenopathy or concerning lesions. At reassessment, she
had a 4 % positive cryofibrinogen level. Despite two
lymph node biopsies and two bone marrow biopsies
there was no evidence of LPD on flow cytometry and
histology.
In January 2014, 2 years after the initial diagnosis of
ITG, the patient presented with a 2-week history of a
painless, enlarging left palatal mass. This mass was pink,
smooth and firm with no redness, warmth or ulceration.
On biopsy, the lesion was found to be a Diffuse Large B
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cell Lymphoma (DLBCL). The morphology was not con-
sistent with other aggressive lymphoma subtypes such as
plasmablastic or Burkitt lymphoma. By immunohisto-
chemistry, lymphocytes were positive for CD20, BCL-2,
BCL-6 (weak), and MUM-1 and negative for CD 3, CD
10, CD 5 and CD 30. Ki-67 stains revealed a prolifera-
tion rate of 90–95 %. Fluorescence in-situ hybridization
(FISH) revealed no rearrangements in C-MYC, BCL-2
and BCL-6.
This patient was diagnosed with a stage IV diffuse
large B cell lymphoma (DLBCL) with imaging confirm-
ing nasopharyngeal and palatal involvement. She
received 6 cycles of R-CHOP combined with 4 cycles of
high dose methotrexate chemotherapy for central
nervous system prophylaxis. She subsequently received
total dose of 30 Gy to the nasopharynx area with
Intensity Modulated Radiation Therapy (IMRT).
Seven months post-R-CHOP and IMRT, she was in
complete remission of her DLBCL confirmed with CT and
Positron Emission Tomography (PET) imaging. Moreover,
her urinalysis was negative for blood and protein with rare
cells and one cellular cast on microscopy. The 24-h urine
collection had 102 mg of protein (Table 2). This indicated
a complete remission of the proteinuria from ITG.
Conclusions
Patients with MGRS due to ITG may inevitably develop
malignant hematopoietic neoplasms. Pharmacologic
treatment can be effective when directed towards a
definitive underlying pathologic diagnosis [2, 6, 7]. As
CLL is the most commonly recognized underlying LPD
in ITG, some experts have suggested treating with
agents known to be effective in CLL [8]. However, there
is a heterogeneity in underlying LPD diagnoses. Our
patient, for instance, had DLBCL and CLL treatment
would have been non-curative. Moreover, Nasr et al. [6]
found that amongst 16 patients with ITG, 3 had CLL
but 2 had lymphoplasmacytic lymphoma and another 2
had myeloma. Bridoux et al. [2] prospectively studied 14
ITG patients with 6 patients diagnosed with CLL and 1
with small lymphocytic B-cell lymphoma. Most LPD
diagnoses were either made prior to or concurrent with
MGRS recognition. ITG remission was achieved in most
patients treated with chemotherapy directed against the
LPD [2, 6]. Heterogeneity in treatment and toxicity of
chemotherapy agents prevents a clear ability to predict
which agents may be most effective without a definitive
pathologic diagnosis. As such, close monitoring for dis-
ease progression with excisional biopsies of lymph nodes
or full cytogenetic and molecular testing of bone mar-
row specimens is recommended.
This case highlights the importance of continued vigi-
lance in patients diagnosed with ITG for development of
a LPD. Our patient initially presented with MGRS due
to ITG. There was likely an insidious clonal process
which declared itself as a DLBCL after a prolonged lag
time. However, the possibility of MGUS converting into
DLBCL or co-occurrence of a novel DLBCL cannot be
difinitively excluded. Even though most ITG patients
who do develop LPDs are diagnosed before or concur-
rently, there are a few who may develop LPD late. Due
to minimal long-term follow-up data for ITG patients, it
is difficult to determine a specific follow-up duration.
However, close follow-up is essential as treatment of the
underlying LPD can allow complete remission of ITG.
Perhaps, with time, evidence may develop supporting a
specific therapeutic regimen which may be employed at
the time of the diagnosis of the MGRS even in the
absence of a specific LPD diagnosis.
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Note: Conversion factor for units: urea in mmol/L to mg/dL, x2.80;creatinine in
umol/L to mg/dl, x0.0113
aModification of Diet in Renal Disease (MDRD) equation based GFR calculation
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